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Africa: A Position Paper
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ABSTRACT
With the global increase in the use of traditional and complementary remedies for the prevention and treatment
of illness, the quality and safety of these medicines have become a significant concern for all regulatory
authorities. Herbal medicines are the most commonly used form of traditional and complementary medicines
in the world and the efficacy and safety of herbal medicines, like conventional medicines, largely depends on
their quality from planting to harvesting, preprocessing and final processing.
Due to the inherent complexity of herbal medicines, often containing an array of active compounds, the
primary processing of herbal medicines has a direct influence on their quality. Quality concerns are the reason
why the medicines regulatory agencies insist that manufacturers of medicines strictly follow Good
Manufacturing Practices since it is an essential tool to prevent instances of contamination, mix-ups, deviations,
failures and errors. However, a strict application of GMP requirements is expensive and would drive the prices
of the manufactured products up. As a result, a maturity level grading of facilities is proposed as a way of
justifying the costs incurred for manufacturers desiring to reach a broader market and investing in continuous
improvement.
36 Good Manufacturing Practice (GMP) inspection reports of local herbal manufacturers conducted by
National Drug Authority were analyzed to establish the type and extent of deficiencies to GMP requirements
for local herbal manufacturers in Uganda. The different GMP chapters and related sub-parameters constituted
the variables used for the analysis of conformity to requirements. The primary outcome variable was the
conclusion regarding compliance or noncompliance of the inspected local herbal manufacturing facility. GMP
parameters that were frequently defaulted by local herbal manufacturers and the corresponding frequencies
were identified. The Pearson Chi-square test was applied independently on each category to find the association that
existed between conformity and the questions in each category.
Only 22% (8) of the 30 inspected facilities were found to comply with GMP requirements, as per National
Drug Authority (NDA) guidelines; while the majority of the facilities, 28 (78%), were found not to comply.
Of the facilities inspected, 25 were undergoing GMP inspection for the first time. A total of 1,236 deficiency
observations were made in the 36 inspection reports reviewed for the study. The mean for all deficiencies was
34.3, and the standard deviation was 15.829. 91.5% of the facilities did not have mechanisms for a record
of market complaints; 80.9% did not meet documentation requirements; 78.9% did not have quality control
measures in place, and 65.7% did not meet stores requirements.
By encouraging a culture of self/voluntary improvement through the introduction of listing of manufacturers
based on a maturity level grading, the National Drug Authority will improve the Herbal Medicines sector as
per the mandate of improving the herbal medicine industry. Also, increased sensitization of all relevant
stakeholders regarding the requirements for GMP should be intensified.
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1. INTRODUCTION
1.1. Historical Perspectives of Traditional Medicines

Traditional and complementary remedies have been
deeply embedded in the lifestyle of ancient peoples
and have been employed in the prevention and
treatment of illness (Lemonnier, 2017). Traditional
and complementary medicine is a vital health resource
in the prevention and treatment of chronic diseases
of the ever-ageing world populations (World Health
Organization, 2019b). Natural products have provided
good medicinal leads in search of new medicinal
compounds. Several well-known medicines that are
currently in use are derived from plant sources such
as Artemisinin, Quinine, Vincristine and Aspirin.
The most frequent sources of traditional medicines
are herbal, but animal and mineral materials are also
sources. Mahomoodally considers Africa to be the
cradle of humankind due to its abundant biological
and cultural diversity, especially regarding differences in
healing practices (Mahomoodally, 2013).
1.2. EAC Potential for the Development of Traditional
Medicine

East Africa will greatly benefit from investing in the
development of its traditional medicine as a source
of foreign exchange earnings and as an alternative to
contemporary medicine in solving the public health
challenges that the region is currently tackling. (East
African Community, 2017) As of 2008, the traditional
medicines global market stood at about USD 83
billion annually and continues to increase. (East
African Community, 2017) Indeed, with about 40,000
to 45,000 species of plants with a potential for
development, only 5,000 species have been used
medicinally. With such biodiversity, Africa has great
potential that is still unutilized and waiting to be
discovered (Mahomoodally, 2013). However, the
most significant danger to this enormous potential is
the rapid loss of most of these natural plant habitats
as a result of human activities. With very high rates of
deforestation reported at 0.7% per annum, there isa
need to regulate the preservation of these species
(FAO, 2006). Besides, there has been a rapid loss
of valuable traditional knowledge due to lack of
permanent documentation of these remedies in Africa
(Mahomoodally, 2013).

of their national health care systems (World Health
Organization, 2013). However, previous works in
other countries and healthcare fields reveal many
challenges facing this proposed integration of
traditional medicine into mainstream national health
care systems (Kayombo et al., 2007).
Like the WHO policy on traditional medicines, the
Uganda National Health Policy 2015 provides for
maximization of the benefits of Traditional and
Complementary Medicines (TCM) and protection of
the public against their possible adverse effects. The
achievement of this objective depends on establishing
and operationalization of an appropriate structure to
promote, coordinate and monitor the implementation
of multi-sectoral traditional and complementary
medicines activities in Uganda (MOH, 2015).
Likewise, the National Drug Authority (NDA),
established by the National Drug Policy and Authority
Statute in 1993, is mandated to encourage and facilitate
research and development of herbal medicines in the
country. Section 41(1) of the National Drug Policy
and Authority (NDP/A) Act, Cap. 206 states that “The
National Drug Authority shall encourage research by
persons carrying on research and development in
herbal and other medicines and, where appropriate,
take such medicines into production as a component
of the drug supply” (National Drug Policy and
Authority Act, 1996).
1.3. Good Manufacturing Practices in Herbal Medicine Manufacture

The inherent complexity of the composition of herbal
medicine, consisting of tens of compounds, along with
the number and small quantity of well-defined active
ingredients, make Good Manufacturing Practices an
essential tool to assure the quality of herbal medicines.
The WHO recognizes that the production and primary
processing of herbal medicines critically determines
the quality of the finished product (World Health
Organization, 2007).

Good manufacturing practices are those control
measures that ensure which products are produced
and controlled in conformance with quality standards
fitting to their intended use and as required by the
The World Health Organization (WHO) policy on marketing authorization (PIC/S, 2013; World Health
traditional medicine aims to facilitate countries to Organization, 2011). The manufacturing process is
develop strategies to make traditional medicine part the critical step required to ensure the quality of all

medicinal products, including herbal medicines.
It has been demonstrated that when manufacturers of
medicines adopt GMP controls, they produce
medicines with the expected identity, strength, quality
and purity (U.S. Food & Drug, 2020). Manufacturers
are expected to buy and use quality raw materials for
the production of medicines. They are also expected
to establish standard operating procedures to be
meticulously followed during production with no
process steps skipped. They should have systems to
detect and investigate product quality deviations and
maintain reliable testing laboratories. The reason why
regulatory bodies demand strict adherence to these
practices is to prevent instances of contamination,
mix-ups, deviations, failures and errors (PIC/S, 2013;
World Health Organization, 2013).
1.4. Adverse Drug Reactions Due to Herbal Medicines

The public generally believes that herbal medicines
are very safe and devoid of adverse effects because
they are found in nature. However, studies have
shown that herbs are capable of producing many
undesirable reactions. Ekor demonstrated that some
of these herbal remedies had caused severe injuries,
life-threatening conditions and even death. Many
irrefutable cases of poisoning as a result of intake of
herbal remedies have been reported in the literature
(Ernst, 2002). Auerbach et al. (2012) reported an
association between traditional herbal medicine use
and the development of liver fibrosis among study
participants in Uganda (Auerbach et al., 2012). In
most countries, manufacturers or importers sell herbal
medicines and related products into the market without
any mandatory safety or toxicological evaluation.
Since very few people using herbal medicines inform
their primary care physicians, many adverse drugs
reactions likely go unrecorded (Ozioma & Okaka,
2019).

WHO and other international organizations have
recognized the circulation of substandard and
falsified medicines as a global problem affecting all
medicines, medical consumables, lifestyle products,
as well as herbal medicines. Ernst has reported an
increase in the rate of adulteration of herbal medicine
with extraneous chemical substances or banned drugs
(Ernst, 2002).
Herbal medicines are adulterated with undeclared
drugs/chemical substances, together with being
substituted with non-drug components and other
foreign non-drug materials. Some manufacturers have
been found culpable for intentional adulteration(Xu,
et al., 2019). Between 2007 and 2016, Tucker
reported that 776 dietary supplements marketed for
sexual enhancement, weight loss or muscle building
in the United States of America contained unapproved
pharmaceutical ingredients (Tucker et al., 2018).
The National Drug Authority surveyed herbal
products claimed to enhance sexual activity in the
central division of Kampala to isolate and identify
adulterants. A total of 49 samples was randomly
collected and screened for the presence of adulterants.
75% of imported herbal products contained unreported
added conventional medicine, whereas the prevalence
of adulteration for locally manufactured herbal
products was 49% (National Drug Authority, 2020b).
These reports show the high rate of counterfeiting of
these products due to the lack of rigorous checks as
compared to conventional medicines.
1.6. Study Justification

Although adherence to Good Manufacturing Practices
(GMP) is a crucial step in ensuring the quality of
herbal medicines, conforming to GMP requirements
requires investment from manufacturers. It is
estimated that small manufacturers would have to
incur 7.2% of annual income to establish and maintain
GMP requirements which eventually impacts on the
affordability of the medicines (InstantGmp, 2002).
Therefore, strict adherence to all parameters in
standard GMP guidelines may not help the National
Drug Authority achieve its mandate of encouraging
research and development of herbal medicines.

There are direct and indirect causes of adverse events
arising from the use of herbal medicines. Some herbs
have been shown to have intrinsic toxicity at the usual
therapeutic dosage, or in overdose. Other adversedrug
reactions are caused by contamination with toxic
metals, other adulteration or by substitution of herbal
ingredients or improperly produced products (Zhang The overall objective of the study was to determine
et al., 2012) and wrong indications and herb-drug compliance with GMP guidelines for herbal
interactions (Zhang et al., 2015).
manufacturers in Uganda. The aim was to determine
the common areas of deficiency of local herbal

1.5. Substandard and Falsified Products

manufacturers and propose a risk-based framework Cronbach’s alpha was used to test the internal
consistency of the checklist used to assess GMP for
for maturity grading of local herbal manufacturers.
local herbal manufacturers which was the basis for the
reports included in the study. It was found that thetool
2. METHODOLOGY
was highly reliable (Cronbach’s alpha=0.95).
2.1. Research Design

The study used a literature review research design
through an assessment of existing Good
Manufacturing Practice inspection reports forlocal
herbal manufacturers in Uganda conducted by
National Drug Authority. The study was both
descriptive and analytical. The descriptive approach
focused on the quantitative aspect of the study that
involved obtaining information regarding the
parameters of GMP evaluated as provided for in the
GMP guideline currently in use for inspection of local
herbal manufacturers. The analytical part evaluated
the current practice compared with other NRAs.
Adaptation of these GMP parameters to the country’s
situation and level of sophistication of the majority of
the local manufacturers were made in order to realize
the mandate of NDA in improving the standards of
locally manufactured herbal medicines.
2.2. Study Population

The study focused on reports generated from GMP
inspections of local herbal manufactures in Uganda.
The study population included all manufacturers who
had undergone GMP inspection by the time this study
was conducted. A total of 36 reports were included in
the analysis. All completed GMP reports of previous
inspections of local herbal manufacturers in Uganda
were obtained from the NDA repository and included
in the study.

2.5. Data Analysis

The primary outcome variable was the conclusion
regarding compliance or noncompliance of the
inspected local herbal. Different activities carried out
by inspected facilities included cultivation of
medicinal plant materials, manufacture of herbal
medicine, packaging and importing. Their frequencies
were determined using SPSS/20. The GMP inspection
checklist titles/chapters were used to identify the
GMP parameters that are frequently defaulted bylocal
herbal manufacturers. These constituted the measures
of conformity and are categorized into ninegroups
including;
• Premises
• Location and surroundings
• Stores
• Sanitation and hygiene
• Machinery and equipment
• Documentation
• Market complaints
• Production area
• Quality control.
1 • Rate of Compliance to Good Manufacturing practices (GMP)
requirements by Local herbal manuacturers in Uganda

2.3. Data Collection Methods

The secondary data for this study was obtained from
the completed GMP inspection reports. Variables were
identified by the different aspects contained in the
National Drug Authority GMP inspection checklist
containing the different GMP parameters considered
by the GMP inspectors. The data obtained from these
reports were collected using a Microsoft Access
database designed for this purpose. The different
GMP inspection reports were coded to enable quicker
cross-referencing of data captured in the database to
ensure the validity of data captured. The outcomes of
the inspection exercise were also captured in the same
Access database.
2.4. Reliability of the Research Instruments

■

Does not conform to requirements

■ Conform to requiremen ts

Activity

Inspection reports associated
with the activity
No, n (%)

Total

Cultivation of medicinal plant
materials

10 (27.8)

26 (72.2)

36

Collection and storage of medicinal plant material

23 (63.9)

13 (36.1)

36

Manufacture of herbal medicine

32 (88.9)

4 (11.1)

36

Yes, n (%)

Packaging

24 (66.7)

12 (33.3)

36

Importing

5 (13.9)

31 (86.1)

36

Laboratory testing

2 (5.6)

34 (94.4)

36

The National Drug Authority had inspected thirty
local herbal manufacturing facilities by the time of
the review. Of these, 69.4% of facilities were being
inspected for the very first time. Only 23% (7) of
the inspected facilities fulfill the requirements for
compliance to GMP specifications as per National
Drug Authority guidelines. In comparison, the
majority of the facilities 77% (23) do not comply with
the requirements, as shown in Figure 1.

Table 1: Activities carried out by facilities

Pearson Chi-square test was applied independently
on each category to find the association that existed
between conformity and the GMP parameters within
each category.
The significant factors were selected and subjected to
binary logistic regression to determine their
relationship with non-conformity. The primary
outcome of this model was “not conform=1” and
“conforms=0”. Crude odds ratios (core) and p-values
with a statisticalsignificance of 0.05 were presented at
the bivariate level. A multivariable logistics
regression was used to determine independent
variables significantly associated with nonconformity, adjusting for relatedfactors and potential
confounders. Based on the likelihood-ratio (LR), a
stepwise forward selection was used to find
significant variables, retaining thosevariables with pvalues < 0.2. The adjusted odds ratios and their pvalues were reported. The conclusions on the
significance of the relationships were based on a 5%
level of significance.
3. RESULTS

Overall, the most frequently carried out activity by the
facilities was the manufacturing of herbal medicine
(n=32, 88.9%), followed by packaging (n=24, 66.7%)
and collection and storage of medicinal plant material
(n=23, 63.9%) as shown in Table 1. The least carried
out activity was laboratory testing (n=34, 94.4%),
followed by importing (n=31, 86.1%) and cultivation
of medicinal plant materials (n=26, 72.2%) as
summarized in Table 1.
Oral solution dosage forms were manufactured in44%
of inspected facilities, followed by liquids for external
use in 13% of inspected sites. Creams and ointments
were third at 11%. Results for other dosage forms
covered in the inspection are shown in Figure 2. In
addition, results show that only 27.8% of surveyed
reports correspond to facilities engaged in cultivation
of the raw materials used for the production of the
herbal medicines. Evidence needs to be gathered
to demonstrate whether the manufacturers of the raw
materials (API) adhere to Good Agricultural
Practices. These manufacturers would have to be
certified to conduct this cultivation process according
to the set requirements to facilitate traceability. It is
also not clear whether the local herbal manufactures

Figure 2: Dosage forms manufatured by the local herbal manufacturing facilities

Oral Solutions

44%

Dosage forms manufactured

Liquids for external use

13%

Creams and Oitments

11%

Suspensions

9%

Topical solids

7%

Powders for oral

7%

Capsules

-

4%

Tablets

-

4%

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

have contracts with raw material suppliers.

P=0.042), as summarized in Table 2.

3.1. Deficiencies Observed in the Review

Firms with no suitable weighing areas for materials
were approximately eight times more likely not to
conform to GMP standards (aOR=7.71, P=0.012).
Firms with no appropriate weighing scales were
approximately nine times more likely not to conform
to GMP standards (aOR=9.21, P=0.0002). Firms
whose scales were not calibrated regularly were

1,236 deficiencies were observed in 36 inspection
reports reviewed. The average number of deficiencies
was 34.3 per report, with a standard deviation of
15.829 deficiencies. 91.5% of the facilities did not
have mechanisms for record of market complaints.
There was an 80.9% rate of noncompliance to

Record of market complaints

91.5%

Documentation

80.9%

Quality control

78.9%

Stores

65.7%

Machinery & Equipment

62.7%

Production area

61.8%
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Figure 3: Rate of nonconformance to GMP requirements per inspection parameter

documentation requirements, 78.9% noncompliance
to quality control requirements and 65.7% rate of
noncompliance to requirements for stores, as shown
in Figure 3. These results indicate that very few
products manufactured by the local manufacturers
would meet any international standards since the
three key control areas: stores, production and quality
control areas have the highest deficiencies.

approximately eight times more likely not to conform
to GMP standards (aOR=8.31, P=0.031). Firms whose
area for weighing was not frequently and adequately
cleaned were five times more likely not to conform
to GMP standards (aOR=5.61, P=0.028). Firms with
no straightforward and illustrative procedure listing
the required basic personal hygiene practices were
approximately seven times more likely not to conform
3.2. Logistic regression results
to GMP standards (aOR=5.61, P=0.001). Firms with
Logistics regression results are summarized in Table 2. no running water for handwashing after use were
Firms without adequate space for equipment, materials approximately 12 times more likely not to conform to
and movement of personnel were approximately five GMP standards (aOR=11.91, P=0.021).
times more likely not to conform to GMP standards
Firms whose personnel were not protected from
(aOR=4.81, P=0.001). Firms whose premises were
contact with toxic irritants and potentially allergenic
not constructed to allow adequate cleaning, good
plant materials using adequate protective clothing
sanitation and hygiene practices were seven times
were approximately nine times more likely not to
more likely not to conform to GMP standards
conform to GMP standards (aOR=8.81, P=0.031).
(aOR=7.12, P=0.041). Firms whose premises had
Firms whose batch manufacturing records were not
no logical flow of activities, material and personnel
kept for all batches were five times more likely not
were two times more likely not to conform to GMP
to conform to GMP standards (aOR=5.31, P=0.0016).
standards (aOR=2.31, P=0.002). Firms whose raw
Firms whose record of sale and distribution of each
materials or ingredients were not identified, inspected
batch of alternative medicines were not maintained
and tested before processing were six times more
were 12 times more likely not to conform to GMP
likely not to conform to GMP standards (aOR=6.14,

standards (aOR=12.31, P=0.031) as shown in Table 2.
Firms whose production area was not adequate to
carry out production activities were eight times more
likely not to conform to GMP standards (aOR=8.05,
P=0.041). Firms whose personnel do not wear
protective gear were six times more likely not to
conform to GMP standards (aOR=6.21, P=0.045).
Firms whose final products were not sampled batchwise for quality testing before being released were nine
times more likely not to conform to GMP standards
(aOR=9.21, P=0.003). Firms with no quality control
laboratory were 13 times more likely not to conform to
GMP standards (aOR=13.01, P=0.014). Firms whose
final product was incorrectly labelled, including the
expiry date, were eight times more likely not to
conform to GMP standards (aOR=8.51, P=0.031) as
summarized in Table 2.

4.2. Rate of Compliance to GMP Guidelines

GMP is aimed at ensuring that products are produced
and controlled according to required quality
appropriate to their intended use and as approved
by the marketing authorization. For the 30 facilities
inspected, only 23% (7) facilities were considered
to fulfill the requirements for compliance with GMP
guidelines for herbal manufacturers in Uganda. In
contrast, the majority of the facilities, 77% (23), did
not comply with the requirements.

The majority of manufacturers rely solely on the
experience of the lead herbalist to ensure thatthe
product is sufficiently produced. Large scale
production requires scale-up and validation of smaller
traditional processes, which are the experience ofthe
lead herbalist. This poses a risk of magnifying errors
arising from scaling up runaway processes thataffect
the quality of the finished products. As a result, these
4. DISCUSSION AND PERSPECTIVES
products cannot comply with intra and inter batch
organoleptic, or chemical consistency tests like
4.1. Demographics
powder fineness, foreign matter and aflatoxin content.
The facilities included in the study mostly Therefore, patients will be exposed to different
manufactured oral solutions (44%), followed by quantities and contents of the drug possibly resulting
liquids for external use (13%) and then creams and in overdose or under-dose.
ointments (11%). Figure 2 shows that most of the
herbal medicines produced by local manufacturers in 4.3. Non-conformances
Uganda are intended for ingestion. This corresponds
Overall, 1,236 deficiencies were made in the 36
to a report by Kumadoh and Ofori-Kwakye (2017)
inspections reviewed for the study. The number of
that identified oral solutions, also known as
deficiencies per facility averaged 34.3 ± 15.8
decoctions. These solutions were prepared by boiling
deficiencies. This is a very high level of deficiencies
the herb in water for a specific time. They were the
observed per facility, with almost half the parameters
most common dosage forms produced by his study
inspected being identified as nonconformances. One
group in Nigeria. These preparations usually were
reason for this high level of nonconformance
recommended to be used immediately within 24 to 48
observations seen in the reports reviewed may have
hours.(Kumadoh & Ofori-Kwakye, 2017) However,
been the high cost required for implementation and
Kumadoh notes that the proliferation of large-scale
maintenance of GMP requirements in a resourceproduction has led to increased shelf-life for herbal
limited setting. Typically, small manufacturers would
products without review of stability data.(Kumadoh
have to incur 7.2% of annual income to establish and
& Ofori-Kwakye, 2017) The absence of stability data
maintain these requirements (InstantGmp, 2002).
and the generic expiry dates of 1-3 years poses a risk
With rudimentary techniques of manufacture and low
to patients who buy these products as the products
incentives for venture capital investments, it is
may have deteriorated and contained unidentified
difficult for small manufacturers to afford this high
breakdown products not intended for consumption.
level of investment.
(European Medicines Agency, 2007) It is important to
note that the herbal preparations manufactured and Also, a lack of knowledge of GMP requirements
sold in Uganda are subject to a simplified registration could have been a factor in explaining these results
process called “notification”. Stability data for local
since 69.4% (25) reports reviewed in the research
herbal remedies is not required for submission before were for first-time inspections. Only 31.6% of reports
approval for sale is granted.
were for subsequent inspections. The National Drug
Authority has just finalized the implementation of a

GMP inspection framework within the organization. areas ought to be provided, controlled, monitored and
Training of inspectors to conduct inspections and recorded, as required for manufacturing and control
education of herbal manufacturers regarding the task.
regulator’s expectations has begun NDA.
4.5. Most Relevant and Scientific Associations

4.4. Most Relevant Areas of Deficiency

Among the parameters inspected for Good
Manufacturing Practices, absence of mechanisms for
recording of market complaints, noncompliance to
documentation requirements, quality control
requirements and requirements for stores had
significantly more noncompliant GMP observations
than other parameters. 91.5% of the facilities did not
have mechanisms for record of market complaints.
According to the WHO, all product complaints, and
potentially defective products, should be carefully
investigated to identify the root cause according to
written SOPs; and the corrective action should be
taken. This is an essential aspect of GMP because
the review of complaints could reveal that the product
was actually defective and that regulatory action
needs to be taken. In addition, this presents a learning
opportunity for the manufacturer to improve the
product. When defects are detected, measures are put
into place to ensure that they do not recur, hence
saving money that would otherwise be used to
withdraw or rework the product.
There was an 80.9% rate of noncompliance to
documentation requirements. The requirement for
documentation aims to define the specifications and
procedures for all materials and manufacturing
process and quality control. Documentation requirements
ensure that all employees know what to do and when
to do it and ensure that before release of a batch for
sale, authorized persons have all the information
necessary to release of reject the batch. Documents
provide records of an audit trail that will permit
investigation in case of product failure or productrelated complaints. (National Drug Authority, 2020a)
Quality control ensures that relevant tests are carried
out and that materials are released for use, or sale only
after ascertaining that their quality complies with the
requirements. There was a 78.9% noncompliance to
quality control requirements.
A 65.7% rate of noncompliance to requirements for
storage areas was observed in the study. Storageareas
are expected to have sufficient capacity to allow
orderly storage of materials and products, withproper
separation and segregation. Sufficient storage

Significant correlations were observed between
failure to comply with these 4 of the 9 categories
of GMP parameters (independent variables) and
failure to comply with GMP requirements (dependent
variable outcome). These include production areas,
preparation of materials for production, personnel
issues, and quality control deficiencies.
Among the parameters inspected for Good
Manufacturing Practices for production areas, lack
of adequate production space (aOR=4.81, P=0.001),
designs which do not allow for adequate cleaning
(aOR=7.12, P=0.041) and logical flow of materials
(aOR=2.31, P=0.002) were significantly more critical
in predicting failure to comply with GMP
requirements. Unsuitable (aOR=7.71, P=0.012)and
dirty weighing areas (aOR=5.61, P=0.028), together
with inappropriate (aOR=7.71, P=0.012) and
uncalibrated weighing scales (aOR=9.21, P=0.0002),
were significantly more critical in predicting failure to
comply with GMP requirements among GMP
parameters related to the preparation of materials for
manufacturing of products.
Likewise, among the parameters inspected for Good
Manufacturing Practices affecting personnel issues,
lack of running water for handwashing (aOR=11.91,
P=0.021), lack of protection of workers from toxic
materials (aOR=8.81, P=0.031) and absence of
protective gear (aOR=6.21,
P=0.045) were
significantly more critical in predicting failure to
comply with GMP requirements. For parameters
affecting documentation, the issues most significantly
predicting failure to comply with GMP include lack
of traceability mechanisms like keeping of batch
records (aOR=5.31, P=0.0016), and lack of sale and
distribution records (aOR=12.31, P=0.031). Lastly,
among the parameters inspected for Quality Control,
lack of proper quality control mechanisms like the
batch-wise sampling of finished products (aOR=9.21,
P=0.003), lack of QC laboratory (aOR=13.01,
P=0.014) and incorrect labelling of finished products
(aOR=8.51, P=0.031) were significantly more
important in predicting failure to comply with GMP
requirements.

Table 2: Criteria for assigning maturity level (This model is adopted from WHO Global Benchmarking Tool (GBT)
Maturity Level

Risk Rank

Description

Maturity Level 1
(ML1)

High

All GMP parameters that are ranked HIGH risk would constitute the Maturity Level 1
(ML1) and are considered essential for being listed at all after assessment. Omitting
any if these requirements constitutes a high risk to the final consumer since this cannot
guarantee a good and consistent quality product.

Maturity Level 2
(ML2)`

Medium

All GMP parameters ranked as MEDIUM risk would constitute the Maturity Level 2
(ML2), with an evolving quality management system that partially performs essential
GMP functions as regards Herbal products.

Maturity Level 3
(ML3)

Low

All GMP parameters ranked as LOW risk would constitute Maturity Level 3 (ML3), with
a stable and functioning GMP system

Discovery of the leading GMP deficiencies is a
crucial step for regulatory authorities to identify the
root causes of medicines-related issues and prioritize
when allocating resources to improve the industry.
It is useful to adopt an annual review on common
GMP deficiencies to identify high-risk GMP areas for
training, and identifying the GMP inspections to highrisk facilities. (PIC/S., 2013)

GMP parameters with low risk would constitute
Maturity Level 3 (ML3), with a stable and functioning
GMP system. GMP parameters ranked as the medium
risk would constitute the Maturity Level 2 (ML2),
with an evolving quality management system that
partially performs essential GMP functions as
regards Herbal products. All GMP parameters that are
ranked high risk would constitute the Maturity Level
1 (ML1) and are considered essential for beinglisted
4.6. Framework for Maturity Level Grading
at all after assessment. Omitting any of these ML1
The World Health Organization developed the Global requirements constitutes a high risk to the final
BenchmarkingTool (GBT) usedto objectivelyevaluate consumer and cannot guarantee a good and consistent
regulatory systems. The GBT also incorporates the quality product. See figure 4.
concept of ‘maturity level’ or ML (adapted from ISO
9004), allowing WHO and regulatory authorities to During the inspection, the checklist would be used for
assess the overall ‘maturity’ of the regulatory system assessing each GMP parameter. A maturity level
on a scale of 1 (existence of some elements of the would then be assigned based on the maturity level
regulatory system) to 4 (operating at an advanced matrix. The ranking is valid as long as the facility
level of performance and continuous improvement). maintains this level of compliance. This ranking
would be subject to revision upon subsequent GMP
(World Health Organization, 2019a).
inspections. The list showing maturity level for
A similar framework has been developed and is inspected local herbal manufacturers would then be
proposed for use during the evaluation of compliance published on the NDA website.
of Good Manufacturing Practices for local herbal
manufacturers in Uganda. The purpose is to enable 5. CONCLUSION AND
local herbal manufacturers to rise from baseline RECOMMENDATIONS
regulatory compliance to sustained, predictive
practices. This maturity level matrix proposed consists From the results of the review of previous herbal
of 3 levels including Maturity level 3 (ML3 – the manufacturers’ GMP reports, it is clear that National
existence of basic elements of the regulatory system), Drug Authority could do more work to improve the
Maturity Level 2 (ML2 – existence of more proactive herbal medicines sector in the country, as per its
elements of regulatory systems), and Maturity level mandate. The number of non-complying facilities
1 (ML1 – the existence of continuous improvement would have been higher if strict GMP classification of
elements of regulatory system as shown in table 2. The the criticality of deficiencies was used during the
maturity level matrix is developed by categorizing all assessments. When conducting inspections, the NDA
GMP parameters based on risk analysis (probability is also asked to consider the government policy“Buy
to cause cross-contamination and mix-ups) and Uganda Build Uganda.” (Ministry of TradeIndustry
statistical correlation to overall non-compliance to and Cooperatives, 2014) This is a policyto help
indigenous businesses have a fair advantage for their
GMP guidelines as shown in table 3.
products over imported goods. Therefore,

generalizable. It is recommended to conduct a similar
analysis in the future to determine the outcomes of
analysis and compare those with the current results for
similarities or differences.

the regulator, instead of instituting enforcement
measures, is called on to help and guide the facility
to improve in their production processes when
nonconformance observations have been identified.
This weakens the effectiveness in enforcing the law,
thus allowing room for inferior quality products
to circulate on the market. However, if human and
financial resources are effectively utilized to train
local herbal manufacturers on GMP as well as set up
quality control infrastructure and establish quality
specifications for the different products and dosage
forms, the local herbal sector will greatly benefit and
take advantage of the indigenous flora to provide
alternative medicines to the population of Uganda.

Integrate all aspects of quality, including Good
Agricultural Practices, Good Processing Practices and
Good Manufacturing Practices in order to ensurethat
products meet all pertinent the requirements. Any
deviations during the earlier stages of cultivation,
production, and manufacturing can adversely affect
the quality of the final products.
Additionally, there is a need to balance government
priorities of safeguarding the population of Uganda and
helping indigenous manufacturers gain an advantage
under the Buy Uganda, Build Uganda (BUBU) policy.
The government could give protection to companies
that are committed to continuous improvement as
required by the law and discourage those only wanting
to do the bare minimum or produce substandard
products that, instead, harm the general public.

Substantial improvements of the herbal sector will
require intense sensitization of all relevant
stakeholders regarding the requirements for GMPand
the need to produce scientifically backed and
consistent products. Encouraging a culture of self- or
voluntary improvement through the introduction of
listing local herbal manufacturers, based on a maturity
level grading, will further encourage/motivate the
local manufacturers to invest resources in orderto Additionally, there is a need to balance government
receive the recognition of the regulator, hence priorities of safeguarding the population of Uganda and
increasing their reputation and business opportunities. helping indigenous manufacturers gain an advantage
under the Buy Uganda, Build Uganda (BUBU) policy.
A limitation of the study was the small number of The government could give protection to companies
GMP inspection reports for local herbal manufacturers that are committed to continuous improvement as
available for review. This reduced the desired required by the law and discourage those only wanting
research population and, therefore, results may not be to do the bare minimum or produce substandard
products that, instead, harm the general public.
4 : Schematic Model for Development of Risk-Based Herbal GMP Maturity Level Grading
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Table 3: Variables significantly associated with noncompliance to GMP guidelines requirements for Herbal manufacturers
using multivariate logistic regression
Crude analysis

Variables
Is there adequate space for equipment, materials and
movement of personnel and materials?
Are the premises constructed to allow adequate cleaning
and good sanitation and hygiene practices?
Is there a logical flow of activities, material and personnel?
Are raw materials or ingredients identified, inspected and
tested before processing?

Adjusted analysis

Crude OR

P-Value

Adjusted OR

P-Value

Yes

1.0

-

1.0

-

No

3.25

0.002

4.81

0.001

Yes

1.0

-

1.0

-

No

8.71

0.012

7.12

0.041

Yes

1.0

-

1.0

-

No

2.41

0.005

2.31

0.002

Yes

1.0

-

1.0

-

No

3.25

0.026

6.14

0.042

Are there suitable weighing areas of materials?

Yes

1.0

-

1.0

-

No

9.15

0.002

7.71

0.012

Does the facility have appropriate weighing scales?

Yes

1.0

-

1.0

-

No

4.45

0.027

9.21

0.0002

Yes

1.0

-

1.0

-

No

7.25

0.042

8.31

0.031

Yes

1.0

-

1.0

-

No

8.15

0.042

5.61

0.028

Yes

1.0

-

1.0

-

Are scales calibrated regularly?
Is the area for weighing frequently and adequately cleaned?
Is there a clear and illustrative procedure listing the required
basic personal hygiene practices?
Do the above facilities have running water for hand washing
after use?
Are Personnel protected from contact with toxic irritants and
potentially allergenic plant materials by means of adequate
protective clothing?
Are batch manufacturing records kept for all batches?
Is a record of sale and distribution of each batch of alternative medicines maintained?
Is the production area adequate enough to carry out production activities?
Do all the personnel wear protective gear?
Are final products sampled batch wise for quality testing
before being released?
Does the facility have a quality control laboratory?
Is the final product correctly labelled including the expiry
date?
cOR= Crude Odds Ratio, aOR= Adjusted Odds ratio

No

8.25

0.052

6.81

0.001

Yes

1.0

-

1.0

-

No

7.95

0.042

11.91

0.021

Yes

1.0

-

1.0

-

No

6.25

0.012

8.81

0.031

Yes

1.0

-

1.0

-

No

3.55

0.012

5.31

0.0016

Yes

1.0

-

1.0

-

No

8.85

0.007

12.31

0.031

Yes

1.0

-

1.0

-

No

6.05

0.042

8.01

0.041

Yes

1.0

-

1.0

-

No

4.26

0.018

6.21

0.045

Yes

1.0

-

1.0

-

No

7.65

0.039

9.21

0.003

Yes

1.0

-

1.0

-

No

9.23

0.027

13.01

0.014

Yes

1.0

-

1.0

-

No

5.17

0.002

8.51

0.031
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